PE20090683A1 - Peptidos de senalizacion - Google Patents
Peptidos de senalizacionInfo
- Publication number
- PE20090683A1 PE20090683A1 PE2008000211A PE2008000211A PE20090683A1 PE 20090683 A1 PE20090683 A1 PE 20090683A1 PE 2008000211 A PE2008000211 A PE 2008000211A PE 2008000211 A PE2008000211 A PE 2008000211A PE 20090683 A1 PE20090683 A1 PE 20090683A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- seq
- peptide consisting
- refers
- signaling peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 230000011664 signaling Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 238000004873 anchoring Methods 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO QUIMERICO QUE COMPRENDE: A) UN POLIPEPTIDO DE INTERES QUE ES UN POLIPEPTIDO INMUNOGENICO TAL COMO PAPILOMAVIRUS O POLIPEPTIDOS ANTITUMORALES; Y B) i) UN PEPTIDO QUE CONSISTE DE LA SEC ID NO:1 O SEC ID NO:2, O ii) UN PEPTIDO QUE CONSISTE DE LA SEC ID NO:3, SEC ID NO:4 O SEC ID NO:5, ENTRE OTROS. DONDE DICHO POLIPEPTIDO COMPRENDE POR LO MENOS UN PEPTIDO DE ANCLAJE A LA MEMBRANA, UN PEPTIDO SENAL QUE CONSISTE EN LA SEC ID NO:2. SE REFIERE TAMBIEN A UN ACIDO NUCLEICO QUE CODIFICA EL POLIPEPTIDO QUIMERICO, UN VECTOR, UNA PARTICULA VIRAL INFECCIOSA, UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y UN METODO PARA PRODUCIR DICHO POLIPEPTIDO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360020 | 2007-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090683A1 true PE20090683A1 (es) | 2009-06-27 |
Family
ID=39367596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000211A PE20090683A1 (es) | 2007-05-15 | 2008-01-29 | Peptidos de senalizacion |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8415462B2 (es) |
| EP (1) | EP2160402A2 (es) |
| JP (1) | JP2010526548A (es) |
| KR (1) | KR20100021603A (es) |
| CN (1) | CN101743250A (es) |
| AR (1) | AR065074A1 (es) |
| AU (1) | AU2008250521B2 (es) |
| CA (1) | CA2687304A1 (es) |
| IL (1) | IL202120A (es) |
| MX (1) | MX2009012326A (es) |
| PE (1) | PE20090683A1 (es) |
| TW (1) | TW200844230A (es) |
| WO (1) | WO2008138649A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2239330A1 (en) | 2009-04-07 | 2010-10-13 | Institut Pasteur | Neuron generation, regeneration and protection |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| ES2651922T3 (es) * | 2011-11-08 | 2018-01-30 | Institut Pasteur | Polipéptidos de afinidad elevada para MAST2 y usos de los mismos |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| MX366206B (es) | 2012-07-10 | 2019-07-02 | Transgene Sa | Vacuna de antígeno micobacteriano. |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| KR20250034101A (ko) | 2022-07-01 | 2025-03-10 | 트랜스진 | 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질 |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06141873A (ja) * | 1992-03-13 | 1994-05-24 | Chemo Sero Therapeut Res Inst | Ｃ型肝炎ウイルス構成ポリぺプチドをコードする遺伝子が組み込まれたウイルスベクターおよびその利用方法 |
| JPH1023899A (ja) * | 1996-07-10 | 1998-01-27 | Nippon Seibutsu Kagaku Kenkyusho | 有用蛋白質の生産方法 |
| FR2766091A1 (fr) * | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US20030059799A1 (en) * | 2001-07-11 | 2003-03-27 | Takashi Okuda | Modified DNA molecule, recombinant containing the same, and uses thereof |
| AR065076A1 (es) * | 2007-01-30 | 2009-05-13 | Transgene Sa | Vacuna contra el papilomavirus |
| BRPI0810305A2 (pt) * | 2007-05-15 | 2018-07-10 | Transgene Sa | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" |
-
2008
- 2008-01-29 AU AU2008250521A patent/AU2008250521B2/en not_active Ceased
- 2008-01-29 KR KR1020097026120A patent/KR20100021603A/ko not_active Ceased
- 2008-01-29 JP JP2010507859A patent/JP2010526548A/ja active Pending
- 2008-01-29 CN CN200880024766A patent/CN101743250A/zh active Pending
- 2008-01-29 EP EP08708352A patent/EP2160402A2/en not_active Withdrawn
- 2008-01-29 US US12/600,460 patent/US8415462B2/en not_active Expired - Fee Related
- 2008-01-29 CA CA002687304A patent/CA2687304A1/en not_active Abandoned
- 2008-01-29 WO PCT/EP2008/051035 patent/WO2008138649A2/en not_active Ceased
- 2008-01-29 TW TW097103227A patent/TW200844230A/zh unknown
- 2008-01-29 PE PE2008000211A patent/PE20090683A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009012326A patent/MX2009012326A/es active IP Right Grant
- 2008-01-29 AR ARP080100355A patent/AR065074A1/es unknown
-
2009
- 2009-11-12 IL IL202120A patent/IL202120A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008138649A2 (en) | 2008-11-20 |
| AU2008250521A1 (en) | 2008-11-20 |
| AR065074A1 (es) | 2009-05-13 |
| MX2009012326A (es) | 2010-02-10 |
| WO2008138649A3 (en) | 2009-01-08 |
| US20100160227A1 (en) | 2010-06-24 |
| CA2687304A1 (en) | 2008-11-20 |
| JP2010526548A (ja) | 2010-08-05 |
| IL202120A (en) | 2013-08-29 |
| EP2160402A2 (en) | 2010-03-10 |
| TW200844230A (en) | 2008-11-16 |
| US8415462B2 (en) | 2013-04-09 |
| AU2008250521B2 (en) | 2013-04-18 |
| IL202120A0 (en) | 2010-06-16 |
| KR20100021603A (ko) | 2010-02-25 |
| CN101743250A (zh) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090683A1 (es) | Peptidos de senalizacion | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| PE20110310A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas | |
| MX359680B (es) | Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores. | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| AR069362A1 (es) | Variantes de enzimas asparraginasas y sus usos | |
| MX2011011960A (es) | Peptidos penetradores de celulas. | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
| AR070058A1 (es) | Enzima bacteriana asociada con la sintesis de ecuol | |
| NZ628756A (en) | Immunogens for hiv vaccination | |
| EP2374892A3 (en) | Expression of viral proteins in plants | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| PE20091214A1 (es) | Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion | |
| PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| MX2019003360A (es) | Vectores de expresion para una secrecion de proteina mejorada. | |
| ES2531115T3 (es) | Combinaciones de clados de RrgB neumocócicos | |
| CY1118861T1 (el) | Αναγνωριση εξω-κυτταρικης μορφης του ρτεν που μπορει να χρησιμοποιηθει για την θεραπεια ογκων | |
| ES2531402T3 (es) | Colagenasa de fusión a la que se une una marca de afinidad, y método para producir la misma | |
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| NZ590011A (en) | Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |